Dinaciclib is an inhibitor of CDK5, an activator of the RALs, shown to reduce pancreatic cancer initiation, progression and metastasis in mouse xenograft models by reducing activation of RALA and RALB [76,192]. The gene discussed is RALB; the disease is pancreatic neoplasm.